Prolactinoma in Aggressive Invasive Pituitary Adenoma with Persistent Growth Despite Maximal Dopamine Agonist Therapy
Clinical Scenario
This protocol targets prolactinoma presenting as an aggressive, invasive prolactin-secreting pituitary adenoma — defined by an unusually rapid growth rate or by clinically relevant growth that continues despite maximal tolerated dopamine agonist doses — with documented persistent adenoma growth despite exhausting all available treatment modalities.
In this refractory setting, management involves escalation to a chemotherapeutic agent. The specific agent, evaluation schedule, and continuation criteria are detailed in the full structured protocol.
Treatment Goals
- At least partial remission with measurable mass shrinkage
- Response formally assessed at 3 months; continuation guided by ongoing response
References
DOI: 10.1038/s41574-023-00886-5
- Aggressive prolactinomas are defined as invasive adenomas with an unusually rapid growth rate or adenomas with clinically relevant growth despite maximal tolerated dopamine agonist doses (strong).
- In patients with aggressive prolactinomas and documented persistent adenoma growth despite exhausting all treatment modalities, the chemotherapeutic agent temozolomide is recommended (strong).
- Response to temozolomide should be evaluated after 3 months and treatment continued for at least 6 months in responsive patients (strong) or for as long as responses are observed (weak).
View source ↗